Advanced Breast Cancer Clinical Trial
— EvoPAR-BR01Official title:
A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)
The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+, 2+/ ISH non-amplified) advanced breast cancer.
Status | Not yet recruiting |
Enrollment | 500 |
Est. completion date | July 18, 2030 |
Est. primary completion date | March 30, 2029 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 130 Years |
Eligibility | Inclusion Criteria: - Adult females, pre/peri-menopausal and/or post-menopausal, and adult males - Histologically or cytologically documented diagnosis of HR-positive, HER2-negative breast cancer - Advanced breast cancer with either locally advanced disease not amenable to curative treatment or metastatic disease - ECOG performance status of 0 or 1 with no deterioration over the previous 2 weeks - FFPE tumour tissue from each participant - Documented germline tumour loss of function mutation in BRCA1, BRCA2, or PALB2 - Adequate organ and marrow function Exclusion Criteria: - Participants with history of MDS/AML or with features suggestive of MDS/AML - Participants with any known predisposition to bleeding - Any history of persisting severe cytopenia - Any evidence of severe or uncontrolled systemic diseases or active uncontrolled infections - Refractory nausea and vomiting, chronic GI disease, inability to swallow the formulated product, or previous significant bowel resection - History of another primary malignancy - Persistent toxicities (CTCAE Grade = 2) caused by previous anti-cancer therapy excluding alopecia - Spinal cord compression, brain metastases, carcinomatous meningitis, or leptomeningeal disease - Evidence of active and uncontrolled hepatitis B and/or hepatitis C - Evidence of active and uncontrolled HIV infection - Active tuberculosis infection - Cardiac criteria, including history of arrythmia and cardiovascular disease - Concurrent exogenous reproductive hormone therapy or non-topical hormonal therapy for non-cancer-related conditions - Major surgical procedure or significant traumatic injury within 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study - Palliative radiotherapy with a limited field of radiation within 2 weeks or with wide field of radiation or to more than 30% of the bone marrow within 4 weeks before the first dose of study treatment - Prior treatment with systemic anti-cancer therapy for locoregionally recurrent or metastatic disease is not permitted, apart from treatment with ET up to 28 days before randomisation - Prior treatment within 28 days with blood product support or growth factor support - Any systemic concurrent anti-cancer treatment - Concomitant use of the following types of medications or herbal supplements within 21 days or at least 5 half-lives of randomisation: 1. Strong and moderate CYP3A4 inducers/inhibitors 2. Sensitive CYP2B6 substrates 3. Substrates of CYP2C9 and/or CYP2C19 which have a narrow therapeutic index, eg, warfarin (and other coumarin-derived vitamin K antagonist anticoagulants) and phenytoin. - Concomitant use of drugs that are known to prolong QT and have a known risk of TdP - Systemic use of atropine - The following exclusion criteria apply to treatments administered for early breast cancer: 1. Disease progression = 84 days following the last dose of neo-adjuvant or adjuvant chemotherapy 2. Disease progression = 1 year (365 days) from the last dose of treatment with a PARPi and/or platinum agent for early breast cancer 3. Disease progression = 1 year (365 days) from the last dose with a CDK4/6i in the adjuvant setting 4. Disease progression = 1 year (365 days) from the last dose of an oral SERD including camizestrant. |
Country | Name | City | State |
---|---|---|---|
Canada | Research Site | Montreal | Quebec |
Canada | Research Site | Montréal | Quebec |
Canada | Research Site | Saskatoon | Saskatchewan |
Canada | Research Site | Toronto | |
Canada | Research Site | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-Free Survival | PFS is defined as time from randomisation until progression per RECIST v1.1 as assessed by BICR, or death due to any cause. | Up to approximately 59 months | |
Secondary | Overall Survival | OS is defined as the time from randomisation until the date of death due to any cause. | Up to approximately 88 months | |
Secondary | Progression Free Survival 2 | PFS2 is defined as the time from randomisation to the earliest of the progression event (following the initial investigator-assessed progression), after first subsequent therapy, or death. | Up to approximately 59 months | |
Secondary | Time to chemotherapy | Time to chemotherapy is defined as time from randomisation until the start date of the first subsequent chemotherapy treatment after discontinuation of randomised treatment (censoring participants who died prior to initiation of chemotherapy). | Up to approximately 59 months | |
Secondary | Objective Response Rate | ORR is defined as the proportion of participants who have a complete or parial response, as determined by BICR per RECIST v1.1. | Up to approximately 59 months | |
Secondary | Duration of Response | DoR is defined as the time from the date of first documented response until date of documented progression per RECIST v1.1 as assessed by BICR, or death due to any cause. | Up to approximately 59 months | |
Secondary | Participant-reported tolerability | Proportion of all dosed participants reporting different levels of severity of diarrhoea as measured by the diarrhoea single item (EORTC IL237/IL239/IL240) and different levels of severity of abdominal pain as measured by the abdominal pain single item (EORTC IL237/IL239/IL240). | Up to approximately 59 months | |
Secondary | Time to deterioration in patient-reported global health status/QoL as measured by the global health status/QoL scale within the The European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) | This scale includes 2 items asking participants to report overall health and overall quality of life in the past week. Both items are measured on a 6-point verbal rating scale ranging from Very Poor to Excellent. Single item scores are averaged to calculate a subscale score that is transformed to range from 0 to 100, where higher scores indicate better global health status/QoL. | Up to approximately 59 months | |
Secondary | Change from baseline in patient-reported global health status/QoL as measured by the global health status/QoL scale within the The European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) | This scale includes 2 items asking participants to report overall health and overall quality of life in the past week. Both items are measured on a 6-point verbal rating scale ranging from Very Poor to Excellent. Single item scores are averaged to calculate a subscale score that is transformed to range from 0 to 100, where higher scores indicate better global health status/QoL. | Up to approximately 59 months | |
Secondary | Plasma concentrations of saruparib (AZD5305) | Up to approximately 59 months | ||
Secondary | Plasma concentrations of camizestrant | Up to approximately 59 months | ||
Secondary | Samples will be used to develop companion diagnostics by analyzing their performance characteristics and calculate their consistency with clinical trial assays used for enrolment onto the study. | Samples will be tested by a CDx to confirm BRCA1/2 and PALB2 gene mutation status | Up to approximately 59 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04653740 -
Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer
|
N/A | |
Completed |
NCT02091960 -
A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05156619 -
Health Care Disparities in Culturally Diverse, Special Needs & Disadvantaged Populations - Bridging the Gap
|
||
Recruiting |
NCT05173103 -
Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer
|
||
Withdrawn |
NCT05191004 -
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
|
Phase 1/Phase 2 | |
Completed |
NCT00754325 -
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
|
Phase 2 | |
Recruiting |
NCT04953377 -
PFMT Educational Intervention for Patients With Advancer Breast Cancer
|
N/A | |
Completed |
NCT03240224 -
Bioinformation Therapy for Breast Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT06193525 -
FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test
|
Phase 2 | |
Completed |
NCT03312738 -
A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor
|
Phase 2 | |
Active, not recruiting |
NCT05063786 -
Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)
|
Phase 3 | |
Recruiting |
NCT05655598 -
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
|
Phase 1 | |
Active, not recruiting |
NCT02499146 -
Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT00445458 -
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04456855 -
Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients
|
||
Completed |
NCT04408118 -
First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC
|
Phase 2 | |
Recruiting |
NCT04222413 -
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT03205761 -
Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer
|
Phase 2 | |
Withdrawn |
NCT04316169 -
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
|
Phase 1 | |
Completed |
NCT00546104 -
Phase II Dasatinib Study in Advanced Breast Cancer
|
Phase 2 |